Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Setanaxib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Calliditas Provides Setanaxib Patent Update
    Calliditas Provides Setanaxib Patent Update

    18 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/calliditas-provides-setanaxib-patent-update-302175403.html

    PR NEWSWIRE
    18 Jun 2024
    Share Share
    R&D Day: Setanaxib Anti-Fibrotic Effects, TARPEYO MoA
    R&D Day: Setanaxib Anti-Fibrotic Effects, TARPEYO MoA

    16 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/in-person--virtual-rd-day-the-anti-fibrotic-effects-of-setanaxib-and-tarpeyos-mode-of-action-302147989.html

    PR NEWSWIRE
    16 May 2024
    Share Share
    Calliditas announces positive topline results from phase 2 , setanaxib
    Calliditas announces positive topline results from phase 2 , setanaxib

    07 May 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168954&sid=2

    PHARMABIZ
    07 May 2024
    Share Share
    Calliditas: Positive Phase 2 Head/Neck Cancer Data For NOX Inhibitor
    Calliditas: Positive Phase 2 Head/Neck Cancer Data For NOX Inhibitor

    06 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/calliditas-announces-positive-topline-results-of-phase-2-head-and-neck-cancer-trial-with-lead-nox-inhibitor-candidate-setanaxib-302136510.html

    PR NEWSWIRE
    06 May 2024
    Share Share
    Calliditas’ setanaxib to receive US patent “Use of NOX Inhibitors for Cancer”
    Calliditas’ setanaxib to receive US patent “Use of NOX Inhibitors for Cancer”

    08 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168410&sid=2

    PHARMABIZ
    08 Apr 2024
    Share Share
    Calliditas Receives Notice of Allowance for US Patent Covering Setanaxib
    Calliditas Receives Notice of Allowance for US Patent Covering Setanaxib

    08 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-setanaxib-in-cancer-treatment-302110166.html

    PR NEWSWIRE
    08 Apr 2024
    Share Share